Telesta Therapeutics (TSE:TST) Given Coverage Optimism Score of 1.90

Press coverage about Telesta Therapeutics (TSE:TST) has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Telesta Therapeutics earned a coverage optimism score of 1.90 on their scale. InfoTrie also assigned press coverage about the biotechnology company an news buzz score of 8 out of 10, meaning that recent press coverage is very likely to have an effect on the stock’s share price in the next few days.

Telesta Therapeutics has a fifty-two week low of C$0.69 and a fifty-two week high of C$0.14.

About Telesta Therapeutics

Telesta Therapeutics Inc is a human therapeutics company. The Company is a biotechnology company, which is focused on the licensing/acquisition and development of transformational therapeutics for the treatment of human diseases, such as cancer, immune diseases and targeted rare diseases. The Company focuses on developing drug candidate, Mycobacterium phlei cell wall-nucleic acid complex (MCNA) for the treatment of non-muscle invasive bladder cancer.

Featured Story: Initial Public Offering (IPO)

Receive News & Ratings for Telesta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.